Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Amyloid Beta and Transition Metals: Structure and Reactivity Updated On: Jan. 19, 2025
Alzheimer's Disease Research Grant

Amyloid Beta and Transition Metals: Structure and Reactivity

Principal Investigator

Veronika Szalai, PhD

University of Maryland Baltimore County

Baltimore, MD, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Standard

Award Amount

$100,000

Active Dates

April 01, 2003 - March 31, 2006

Grant ID

A2003227

Summary

The diagnosis of Alzheimer’s disease (AD) is determined by the appearance of neuro-fibrillary tangles and amyloid plaques in brain tissue. Amyloid plaques are composed of repeating units of the protein amyloid-beta (Aß). While the global structure of amyloid plaques has to a great extent been revealed, local structural factors are not well understood. Transition metal ions like copper, zinc and iron have been observed to both increase and decrease the rate of Aß aggregation in vitro. The transition metals may not play an exclusively structural role in the biochemistry of Aß. The levels of copper ions are increased in the vicinity of amyloid plaques, yet decreased overall in AD-affected brains, implying that transition metal ion homeostasis is affected during the progression of the disease. The finding that transition metal ion levels in brains from AD patients are different from the levels in control samples has led researchers to investigate metal ion involvement in the neurotoxic events. In the presence of Aß in a test tube, some transition metals trap dioxygen to generate species that could potentially lead to neurodamage. The purpose of this study is to investigate the chemistry of metal ions in amyloid plaque neurotoxicity. Because a drug that binds metal ion has already been shown to dissolve amyloid plaques in vitro, the results could be helpful in designing new therapeutic strategies. If the mechanisms of the role of metal ions with Aß can be understood, Dr. Szalai’s team may be able to provide a promising new direction for drug design.